Eledon Pharmaceuticals to Present at SVB Securities Global Biopharma Conference

Rhea-AI Summary

Eledon Pharmaceuticals, Inc. announced that CEO David-Alexandre C. Gros will present at the SVB Securities Global Biopharma Conference on February 15, 2023, at 5:00 p.m. ET. Interested participants can register for the presentation webcast here. A replay will be available on the company’s website after the live session. Eledon is developing innovative therapies targeting the CD40 Ligand pathway, including its lead compound, tegoprubart, for organ and cell transplants, autoimmune diseases, and ALS.

IRVINE, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, Chief Executive Officer, will present at the upcoming SVB Securities Global Biopharma Conference on February 15, 2023, at 5:00 p.m. ET.

To register in advance for the presentation webcast, sign up here.

A webcast replay will be accessible following the live session on the Events page of the Investors section on the Company’s website at https://ir.eledon.com/events-and-presentations/events.

About Eledon Pharmaceuticals and tegoprubart (formerly AT-1501) 

Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop potential treatments for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with ALS. The company’s lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential. Eledon is headquartered in Irvine, Calif. For more information, please visit the company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter 

Investor Contact: 

Stephen Jasper 
Gilmartin Group 
(858) 525-2047 
stephen@gilmartinir.com 

Source: Eledon Pharmaceuticals

FAQ

What is Eledon Pharmaceuticals' presentation at the SVB Securities Global Biopharma Conference?

Eledon Pharmaceuticals will have CEO David-Alexandre C. Gros present on February 15, 2023, at 5:00 p.m. ET during the SVB Securities Global Biopharma Conference.

How can I register for Eledon Pharmaceuticals' conference presentation?

You can register for the presentation webcast of Eledon Pharmaceuticals by signing up here.

What is the focus of Eledon Pharmaceuticals' research?

Eledon Pharmaceuticals focuses on developing therapies targeting the CD40 Ligand pathway for organ and cell transplants, autoimmune diseases, and ALS.

What is tegoprubart and its significance?

Tegoprubart is Eledon Pharmaceuticals' lead compound, an anti-CD40L antibody with potential therapeutic applications for organ transplants and autoimmune conditions.